Foghorn Therapeutics Inc 's (FHTX) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Foghorn Therapeutics Inc   (NASDAQ: FHTX)
 



  Foghorn Therapeutics Inc Outlook

On March 7 2024 the Foghorn Therapeutics Inc provided following guidance

Foghorn Therapeutics Inc. has released a financial update for the year 2023 and provided a strategic outlook for 2024. The company is currently focused on dose escalation in their combination study of FHD-286 in Acute Myeloid Leukemia (AML), with progress continuing to be made. They are anticipating the release of clinical data from this study in the second half of 2024. This development is a key milestone for the company as they work towards advancing their innovative therapies for the treatment of cancer. Foghorn Therapeutics Inc. remains committed to driving forward their research and development efforts to bring novel treatment options to patients in need.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.